Akers生物科学 AKER 深 沪
已收盘 04-16 16:00:00 美东时间
2.47
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.47
- 总市值 4113.24万
- 52周最高 41820.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 9900.00
- 委 比 0.00%
- 总股本 1665.28万
- 历史最高 6566400.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 5760.00
- 每 手 1
- 风险率 0.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Results from Akero Therapeutics' Phase 2b HARMONY trial, published in *The Lancet*, demonstrate that efruxifermin (EFX) significantly reduced liver fibrosis and resolved steatohepatitis in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH). At 96 weeks, 49% of participants on 50mg EFX achieved fibrosis improvement without worsening of MASH, compared to 19% on placebo. Additionally, EFX improved liver injury marker...
08-14 22:30
【监管】赶紧卸载！这33款App被通报→
市市场监管局介绍，依据《网络安全法》《个人信息保护法》等法律法规，按照《中央网信办、工业和信息化部、公安部、市场监管总局关于开展2025年个人信息保护系列专项行...
07-29 12:11
官方通报！涉嫌违规，义乌人抓紧自查！
（来源：爱义乌） 近日 据国家网络安全通报中心通报 33款移动应用 存在违法违规收集 使用个人信息情况 其中 驾校宝典、扫描全能王等App在列 快看看有没有...
07-25 19:02
违法违规收集使用个人信息，33款移动应用被通报
转自：北京日报客户端 依据《网络安全法》《个人信息保护法》等法律法规，按照《中央网信办、工业和信息化部、公安部、市场监管总局关于开展2025年个人信息保护系列...
07-23 17:03
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Akebia Therapeutics, Inc., a biopharmaceutical company focused on improving lives of kidney disease patients, announced that its Chief Commercial Officer, Nik Grund, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14 at 10:00 AM EDT. A webcast of the presentation will be available on Akebia's website following the event.
07-08 12:00
创新创业通识课报名｜康文胜：双重身份“过来人”视角漫谈创业和投融资
创燃未来 • INNOVATE X 2025.6.6 {创新创业系列活动} 第二期 Vol.02 通识课程 TOPIC 创业路上总在交学费 如何...
06-05 17:31
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
Akero Therapeutics announced that its management will present at the Jefferies Global Healthcare Conference on June 4, 2025. The presentation will be webcast live and archived on the company's website. Akero develops treatments for serious metabolic diseases like metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, efruxifermin (EFX), is in Phase 3 trials. The company is based in South San Francisco.
05-28 11:00
BIG-TIME BUCKET: WNBA SCORES ALLY FINANCIAL AS OFFICIAL BANKING PARTNER AND NEWEST CHANGEMAKER
--Ally will Serve as the Presenting Partner of the WNBA's First-Ever "Rivals Week," a Thrilling Showcase of Must-See Matchups August 9-17-- --New Sweepstakes from Ally Offers Fans a Chance t...
04-11 21:00
